Clinical Studies Evaluate DermaSensor’s Skin Cancer Detection Device
DermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company's device in detecting skin cancer.
DermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company's device in detecting skin cancer.
Proscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.
Nanopipettes with zwitterionic membranes may offer improved monitoring of changes in pH surrounding living cells, which can indicate traits of invasive cancer cells and their response to treatment.
Study data demonstrate that about half of patients have clinically actionable mutations that are being missed.
Read MoreStudies are demonstrating the potential of the Parsortix system to enhance laboratory efficiency, reduce costs, support medical decisionmaking, and improve patient care.
Read MoreThe research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read MoreProtagen has extended its collaboration with the National Center for Tumor Diseases, Heidelberg, to investigate the immunocompetence of urothelial cancer patients receiving immunotherapy.
Read MoreAlmost two-thirds of the patients with CDKN2A mutations responded with tumors that shrank, and for a third of the patients the tumors disappeared completely.
Read MoreThe partners will apply deep machine learning to develop biomarker models for relevant treatment-associated endpoints such as immune-related adverse events, clinical response, or survival.
Read MoreThe panel accurately and sensitively detects more than 1,600 variants of clinical significance.
Read MoreAnti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read MoreCirculating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read MoreProtagen and Gustave Roussy will partner to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events in cancer patients treated with checkpoint inhibitors.
Read MorePresenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read MoreStudy results have demonstrated that a test based on a protein signature associated with patient outcomes in metastatic melanoma can effectively predict survival among patients receiving programmed cell death-1 antibodies.
Read MoreLed by investigators at the Translational Genomics Research Institute, researchers have identified a protein target that opens a window into acral lentiginous melanoma and may aid in diagnosis.
Read MoreEarly data suggests the test’s clinical potential for guiding anti-PD-1 therapy.
Read MoreAfter its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read More